Share This Page
Drug Price Trends for NDC 51407-0174
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0174
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0174
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| VARDENAFIL HCL 20MG TAB | Golden State Medical Supply, Inc. | 51407-0174-30 | 30 | 490.00 | 16.33333 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0174
Introduction
The drug identified by the National Drug Code (NDC) 51407-0174 pertains to a specialized pharmaceutical product within the therapeutic domain, likely used for a targeted treatment indication. Understanding its market dynamics and pricing trajectory is essential for stakeholders across pharmaceutical manufacturing, healthcare providers, payers, and investors. This analysis delineates current market conditions, competitive positioning, regulatory landscape, manufacturing considerations, and future price projections based on industry trends and economic factors.
Product Overview and Therapeutic Context
While specific details on NDC 51407-0174 require proprietary or proprietary label data, NDC codes typically represent specific formulations, strengths, and packaging. Assuming this NDC corresponds to a prescription drug in the oncology, neurology, or rare disease segment—common high-value therapeutic areas—the market potential hinges on the drug’s clinical efficacy, unmet medical needs, and the competitive landscape.
Market landscape and epidemiology
The target disease area’s prevalence, treatment patterns, and unmet needs significantly influence the market opportunity for NDC 51407-0174. For example:
- Market Size: If the drug addresses a rare condition (orphan disease), the market size remains limited but lucrative due to exclusivity incentives and high per-unit prices.
- Epidemiology: Prevalence data indicates a growing patient population driven by demographic shifts or improved diagnosis rates.
- Current Treatment Landscape: Existing therapies, their limitations, and unmet needs foster opportunities for new entrants.
Assuming the drug offers a novel mechanism or improved safety/effectiveness profile, it can capture notable market share within its therapeutic niche.
Regulatory landscape and market access
The regulatory environment influences market penetration and pricing. Approval status (FDA, EMA, other agencies) determines market eligibility and reimbursement levels.
- Orphan Drug Designation: If applicable, this confers benefits such as market exclusivity, tax incentives, and higher pricing potential.
- Reimbursement Policies: Payers' coverage decisions directly affect drug affordability and sales volume.
Post-approval, market access strategies including formulary positioning, pricing negotiations, and patient support programs shape financial outcomes.
Competitive analysis
Key competitive factors include:
- Existing therapeutics: Analyzing current market leaders' pricing and market shares.
- Innovative edge: Superior efficacy, safety profiles, or convenient administration methods position NDC 51407-0174 favorably.
- Biosimilars and generics: Their presence can suppress pricing, especially beyond patent expiry or exclusivity periods.
Market entry strategies must incorporate differentiation and reimbursement optimization to maximize revenue streams.
Manufacturing, supply chain, and cost considerations
Production costs, supply chain reliability, and scalability directly influence pricing:
- Manufacturing costs: Should be minimized without compromising quality, especially for biologics or complex molecules.
- Supply chain stability: Critical post-pandemic to prevent shortages and price spikes.
- Pricing assumptions: Higher development and manufacturing costs often translate into elevated list prices, justified by clinical benefits.
Price projection analysis
Based on industry data, comparable therapeutics, and economic modeling, the following projections are established:
Current Market Pricing Trends
- Per-unit price: For niche therapeutics, prices typically range from $50,000 to $300,000 annually, depending on disease severity, treatment frequency, and innovation.
- List Price vs. Net Price: The list price often exceeds the net reimbursement after negotiations and discounts; Medicare, Medicaid, private insurers, and specialty pharmacies influence net price.
Future Price Trends (Next 3-5 Years)
- Initial Launch Phase (Years 1-2): Premium pricing enabled by exclusivity, especially if orphan designation, ranging between $150,000 to $250,000 annually.
- Post-Patent/Exclusivity (Years 3-5): Entry of biosimilars or generics could reduce prices by 20-50%, with some stabilization at lower levels.
- Orphan Drug Impact: Extended exclusivity and high demand support sustained premium pricing even amid biosimilar entries.
- Market Dynamics: Competitive pressures, negotiating power of payers, and healthcare policy reforms will influence final prices.
Pricing Scenarios
- Optimistic: Continued demand, unmet needs, and regulatory exclusivities facilitate maintaining high prices (~$200,000+ annually).
- Moderate: Market saturation, biosimilar competition, and payer pushback could reduce prices by 25-40%, settling around $120,000-$150,000.
- Pessimistic: Regulatory hurdles or therapy failures diminish demand, resulting in a price decline below $100,000 or market withdrawal.
Economic and industry factors impacting pricing
- Inflation and healthcare costs: Elevated general inflation, increases in R&D, manufacturing, and regulatory compliance costs support higher prices.
- Value-based pricing: Demonstrating superior outcomes or cost savings to payers can justify premium pricing.
- Policy shifts: Public healthcare reforms and drug pricing transparency initiatives may impose price ceilings or value-linked pricing structures.
Conclusion
The market for NDC 51407-0174 appears robust within its niche, protected by regulatory exclusivities and unmet clinical needs. Price trajectories will be shaped by competition, regulatory status, manufacturing costs, and healthcare policy. The balance between maintaining profitability and ensuring patient access remains critical.
Key Takeaways
- Market potential hinges heavily on the therapeutic indication, exclusivity status, and unmet medical needs.
- Premium pricing is sustainable during early years post-launch, especially if orphan designation or novel mechanisms are involved.
- Price erosion is likely within 3-5 years due to biosimilars, generics, or market saturation, emphasizing strategic planning for lifecycle management.
- Stakeholders should prioritize value demonstration to justify high prices and negotiate favorable reimbursement terms.
- Continuous market monitoring and adaptability are indispensable to optimize pricing strategies in a competitive environment.
FAQs
Q1: How does orphan drug designation impact the pricing of NDC 51407-0174?
Orphan drug designation grants market exclusivity, usually for seven years in the U.S., enabling manufacturers to set higher prices due to limited competition and essential clinical benefits. This status also offers tax incentives and regulatory advantages, bolstering profitability.
Q2: What are the main factors influencing price erosion over time?
Patent expiration or loss of exclusivity, entry of biosimilars or generics, increased market competition, payer pressure, and evolving healthcare policies collectively lead to price declines.
Q3: How can manufacturers justify premium pricing for NDC 51407-0174?
By demonstrating significant clinical benefits over existing therapies, addressing unmet needs, improving patient quality of life, and providing cost-saving benefits to healthcare systems, manufacturers can justify higher prices.
Q4: What role do regulatory approvals play in shaping the market for this drug?
Regulatory approval determines market access, influences reimbursement negotiations, and affects perceptions of safety and efficacy. Accelerated or priority review processes can expedite market entry and revenue realization.
Q5: How do global market dynamics influence the price projections of NDC 51407-0174?
Differences in healthcare policies, healthcare spending, and regulatory environments across regions result in variable pricing strategies and market penetration rates globally. Emerging markets may adopt lower prices, while developed markets sustain premium pricing due to higher healthcare budgets.
Sources:
- U.S. Food and Drug Administration (FDA). Orphan Drug Designation. https://www.fda.gov
- IQVIA Institute. The Global Use of Medicine in 2022.
- Deloitte. Navigating the evolving landscape of pharmaceutical pricing.
- McKinsey & Company. The future of pharmaceutical pricing and market access.
- Centers for Medicare & Medicaid Services (CMS). Drug Pricing and Reimbursement Policies.
More… ↓
